Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate, the active ingredient in Mildronate, is a cardiovascular metabolic modulator presented as an injectable solution for intravenous use. It is used to treat ischemic heart disease, angina pectoris, heart failure and peripheral arterial disease in adult patients.

GNH USA supplies Mildronate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mildronate acts on myocardial energy metabolism and is employed in several ischemic cardiovascular conditions.

Ischemic heart disease: improves myocardial oxygen efficiency and reduces ischemic episodes. Angina pectoris: decreases frequency and severity of chest pain attacks. Heart failure: supports cardiac output and exercise tolerance. Peripheral arterial disease: enhances limb perfusion and alleviates claudication.

Mildronate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache - Nausea - Dizziness - Injection site pain - Mild hypotension - Fatigue

Serious or Rare Side Effects: - Arrhythmia - Severe hypotension - Anaphylactic or allergic reaction - Elevated liver enzymes - Renal impairment - Rare myocardial infarction

When prescribing Mildronate, clinicians should consider several safety measures.

Assess cardiac status before initiation: evaluate severity of ischemic disease. Monitor blood pressure regularly: detect hypotensive episodes. Use cautiously in renal or hepatic impairment: adjust therapy as needed. Avoid in patients with known hypersensitivity to meldonium: discontinue if reaction occurs. Review concomitant anti‑ischemic drugs: watch for additive effects. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Mildronate can interact with other agents affecting myocardial metabolism or hemodynamics.

Major Interactions (Avoid): - Other metabolic modulators (e.g., trimetazidine): risk of metabolic imbalance. - High‑dose catecholamines: may blunt therapeutic effect. - Strong CYP inhibitors (if applicable): potential increased exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive anti‑ischemic effect, monitor heart rate. - Nitrates: enhanced hypotensive response, observe blood pressure. - Anticoagulants/antiplatelets: monitor for bleeding tendencies.